Finding finance for biotechs and indeed the venture capital firms that support them has been extremely tricky of late so the fact that Sofinnova Partners has raised €1.20bn ($1.26bn) in the past year is an impressive feat, chairman Antoine Papiernik has told Scrip.
The whopping fundraising by Sofinnova, which is based in Paris, London and Milan and has established itself as Europe’s leading life science VC, included more than €1bn secured just in the last quarter